TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04180683

Intervention type: OTHER
Intervention: Battery of screening tests with semi-structured interview
Description: First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.

Intervention type: OTHER
Intervention: Battery of screening tests without semi-structured interview
Description: First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
Study: NCT01989793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan will be given in increasing doses to those in the losartan arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to those in placebo arm
Study: NCT04817020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: %2 Klorheksidin
Description: Effect on phlebitis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: %2 Klorheksidin
Description: Effect on phlebitis
Study: NCT00939016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lunch meal with 24 hour dietary recall
Description: Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lunch meal with 24 hour dietary recall
Description: Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
Study: NCT06107712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face yoga exercise
Description: The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.
Study: NCT03876912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: 18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
Study: NCT02101645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodical low intensity direct current (LIDC) stimulation of wound.
Description: Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compression therapy of swollen limbs.
Description: Compression bandage is used for reducing swelling of the limbs.
Study: NCT04251598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Am Protecting My Child from the Sun
Description: The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Am Protecting My Child from the Sun
Description: The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS for sun protection
Description: While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
Study: NCT04482842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene detection (CYP2C9*3, VKORC1)
Description: Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium
Description: Warfarin is administered at a gene-guided dose or at a regular dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin Sodium
Description: Warfarin is administered at a gene-guided dose or at a regular dose.
Study: NCT03414424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES at rest
Description: CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES plus active hand or wrist movements
Description: CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study: NCT04028206

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxymethylbutyrate
Description: Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxymethylbutyrate
Description: Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-magnitude High Frequency Vibration (LMHFV)
Description: Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Elastic-band Exercise
Description: Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching.
Study: NCT03833973

Intervention type: BEHAVIORAL
Intervention: Overtraining Monitoring
Description: Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.

Intervention type: BEHAVIORAL
Intervention: Overtraining Monitoring
Description: Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
Study: NCT02728895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab Injection.
Study: NCT03863223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib, Trastuzumab, Docetaxel
Description: Pyrotinib 400mg orally daily until progressive disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Trastuzumab, Docetaxel
Description: Placebo 400mg orally daily until progressive disease
Study: NCT00970983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadrantectomy and axillary dissection
Description: standard quadrantectomy and axillary dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadrantectomy + sentinel node biopsy
Description: standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
Study: NCT04214886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
Study: NCT02160600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard multiphase CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: split bolus Dual energy CT
Study: NCT04148560

Intervention type: OTHER
Group type: OTHER
Intervention: Tests of the validity of the RFPM and SmartIntake app.
Description: Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
Study: NCT01228500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix
Description: Dermal Repair Scaffold
Study: NCT03035942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study: NCT04183491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon beta-1a 7.5 µg administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon beta-1a 15 µg administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon beta-1a 30 µg administered IM
Study: NCT04214886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34 CAR transduced T cells
Description: CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34 CAR transduced T cells
Description: CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34 CAR transduced T cells
Description: CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34 CAR transduced T cells
Description: CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
Study: NCT02023021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT00376805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: administered intravenously 25 mg/m\^2 times 5 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administered intravenously 60 mg/kg days times 2 doses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy (gray) on day -1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural killer cell infusion
Description: Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: administered subcutaneously (10 MU) 3 times per week for 6 doses
Study: NCT00526110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2.2 Gm/m\^2 IV over 48 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20 mg/m\^2 IV over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 IV over 120 minutes on Day 1.
Study: NCT03693313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CrossFit Kids exercise program
Description: Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CrossFit Kids exercise program
Description: Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
Study: NCT03354832

Intervention type: OTHER
Intervention: Foetal death
Description: A midwife is in charge to interview the mother during the month following the lost of her infant.

Intervention type: OTHER
Intervention: New-born death
Description: A midwife is in charge to interview the mother during the month following the lost of her infant.

Intervention type: OTHER
Intervention: Birth control for foetal death
Description: A midwife is in charge to interview the mother during her hospital stay

Intervention type: OTHER
Intervention: Birth control for new-born death
Description: A midwife is in charge to interview the mother during her hospital stay
Study: NCT03286777

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol and silicon dioxide capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native 6-prenylnaringenin
Description: 250 mg native 6-PN plus mannitol and silicon dioxide capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar 6-prenylnaringenin
Description: 250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
Study: NCT05280327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Application
Description: The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
Study: NCT02926092

Intervention type: DIAGNOSTIC_TEST
Intervention: Observation
Description: Observation of progression of disease over time
Study: NCT01175200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: antiplatelet agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: antiplatelet agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: proton pum inhibitor
Study: NCT03784027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS FX
Description: CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor augmented therapy
Description: Study insulin pump and study CGM.
Study: NCT01175200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator similar to lansoprazole
Study: NCT01605487

Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rupatadine
Description: Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days